• Oruka Therapeutics published its EVERLAST-B interim data presentation on the Phase 2b psoriasis trial of ORKA-001.
• The 600 mg group achieved 61% PASI 100 and 86% PASI 90 response rates at Week 16.
• The 600 mg dose is planned for Phase 3, with initiation expected in the first half of 2027.
• No serious or severe treatment-emergent adverse events occurred in the high-dose group.
• Week 52 EVERLAST-A data are expected in December 2026 to support evaluation of annual dosing potential.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.